Peregrine Capital Management LLC Has $5.67 Million Stock Position in Evolent Health, Inc. (NYSE:EVH)

Peregrine Capital Management LLC raised its stake in Evolent Health, Inc. (NYSE:EVH) by 65.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 503,601 shares of the technology company’s stock after acquiring an additional 198,358 shares during the quarter. Peregrine Capital Management LLC owned about 0.43% of Evolent Health worth $5,666,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Covestor Ltd increased its holdings in shares of Evolent Health by 138.1% in the third quarter. Covestor Ltd now owns 1,424 shares of the technology company’s stock valued at $40,000 after purchasing an additional 826 shares in the last quarter. R Squared Ltd acquired a new stake in shares of Evolent Health in the 4th quarter valued at $31,000. AlphaCentric Advisors LLC bought a new stake in shares of Evolent Health during the fourth quarter worth $61,000. Point72 Asia Singapore Pte. Ltd. lifted its stake in shares of Evolent Health by 2,471.9% during the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 6,507 shares of the technology company’s stock valued at $184,000 after acquiring an additional 6,254 shares during the period. Finally, US Bancorp DE boosted its holdings in Evolent Health by 180.3% in the third quarter. US Bancorp DE now owns 6,579 shares of the technology company’s stock valued at $186,000 after acquiring an additional 4,232 shares during the last quarter.

Evolent Health Stock Performance

EVH stock opened at $10.09 on Wednesday. Evolent Health, Inc. has a 1-year low of $9.45 and a 1-year high of $35.00. The business’s 50-day moving average price is $10.82 and its two-hundred day moving average price is $19.04. The firm has a market cap of $1.18 billion, a PE ratio of -11.09 and a beta of 1.45. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 0.58.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on EVH shares. Needham & Company LLC restated a “buy” rating and set a $15.00 target price on shares of Evolent Health in a research report on Wednesday, February 12th. UBS Group cut their price objective on shares of Evolent Health from $27.00 to $14.00 and set a “buy” rating on the stock in a report on Thursday, January 16th. Stephens reduced their price objective on shares of Evolent Health from $16.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Tuesday, January 21st. Oppenheimer dropped their target price on shares of Evolent Health from $28.00 to $18.00 and set an “outperform” rating for the company in a research report on Friday, January 24th. Finally, JPMorgan Chase & Co. reduced their price target on Evolent Health from $15.00 to $13.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 28th. One analyst has rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $17.92.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.